アブストラクト
| Title | ペグフィルグラスチム (遺伝子組換え) (ジーラスタ(R)皮下注) |
|---|---|
| Subtitle | 特集 急な提案・問い合わせにしっかり備える がん患者の支持療法薬 |
| Authors | 葉山達也 |
| Authors (kana) | |
| Organization | 日本大学医学部附属板橋病院薬剤部 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 9 |
| Page | 1775-1780 |
| Year/Month | 2022 / 7 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●発熱性好中球減少症(FN)リスクが10〜20%のレジメンには, 個別のリスク因子を勘案して予防的投与を実施する. ●ペグフィルグラスチムの至適投与時期は, day3〜4の可能性と考えられる. ●ペグフィルグラスチム誘導骨痛(PIBP)にはリスク因子を考慮した, 予防的介入を実施する. ●造血幹細胞の末梢血中への動員への使用は, 用量が2倍(7.2mg)となり, PIBPを含めた副作用の発現率が顕著に上昇するため留意する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) 協和キリン株式会社 : ジーラスタ(R)皮下注3.6mg, インタビューフォーム(2022年2月改定, 第2版)
- 2) 棄原 隆, 他 ; 穎粒球コロニー形成刺激因子(G-CSF)のファーマコキネティクス 体内動態における受容体介在性クリアランスの寄与. 薬物動態, 11 : 194-208, 1996
- 3) Kuderer NM, et al : Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemo-therapy : a systematic review. J Clin Oncol, 25 : 3158-3167, 2007
- 4) Vogel CL, et al : First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer : a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol, 23 : 1178-1184, 2005
- 5) Green MD, et al : A randomized double-blind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol, 14 : 29-35, 2003
残りの15件を表示する
- 6) Pfeil AM, et al : Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer : a systematic review. Support Care Cancer, 23 : 525-545, 2015
- 7) Hartmann LC, et al : Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med, 336 : 1776-1780, 1997
- 8) Clark OA, et al : Colony-stimulating factors for chemo-therapy-induced febrile neutropenia : a meta-analysis of randomized controlled trials. J Clin Oncol, 23 : 4198-4214, 2005
- 9) Balducci L, et al : Elderly cancer patients receiving chemo-therapy benefit from first-cycle pegfilgrastim. Oncologist, 12 : 1416-1424, 2007
- 10) Smith TJ, et al : Recommendations for the use of WBC growth factors : American society of clinical oncology clinical practice guideline update. J Clin Oncol, 33 : 3199-3212, 2015
- 11) NCCN Guidelines Version2. Myeloid growth factors 2016
- 12) 日本臨床腫瘍学会・編 : 発熱性好中球減少症(FN)診療ガイドライン改訂第2版. 南江堂, 2017
- 13) Aapro MS, et al : 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer, 47 : 8-32, 2011
- 14) Burris HA, et al : Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma : Results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract, 6 : 133-140, 2010
- 15) Zwick C, et al : Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol, 22 : 1872-1877, 2011
- 16) Loibl S, et al : Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemo-therapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study : (GBG 33). Support Care Cancer, 19 : 1789-1795, 2011
- 17) Crawford J, et al : The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol, 8 : 1117-1124, 1997
- 18) Weycker D, et al : Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin, 33 : 2107-2113, 2017
- 19) Hayama T, et al : Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies. Int J Clin Pharm, 40 : 997-1000, 2018
- 20) Kirshner JJ, et al : Prevention of pegfilgrastim-induced bone pain : a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol, 30 : 1974-1979, 2012
